Abbott a top pick for RBC

RBC Capital Markets analyst Phil Nalbone rated Abbott Laboratories a top pick, average risk, with a $55 price target as the company reported in line third-quarter results. Sales of $5.573 billion were up 3.5%, slightly better than the analyst's estimate of $5.521billion. Humira sales were up 52% to $541 million, easily beating RBC's estimate of $509 million. Shares of the Abbott Park, Ill.-based biopharmaceutical company were up 66 cents, or 1.40%, at $47.85. (NYSE: ABT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.